InsidersTradesSigma
Edgewise Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)
SEC:edgewise-therapeutics-inc-58ef88US·SEC (Form 4)Mcap 2.6Bn€Healthcare & Pharma
Explore the full directors' dealings record of Edgewise Therapeutics, Inc., a listed equity based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Edgewise Therapeutics, Inc. has recorded 35 reports. Market capitalisation: €2.6bn. The latest transaction was filed on 21 June 2022 (Levée d'options). Among the most active insiders: Russell Alan J. Every trade is accessible without an account.
35
Insider Decl.
0
Thresholds
€2m
2 ops.
Buy Volume
€2m
21 ops.
Sell Volume
Financial data
33.09 €
Analyst consensus
12 analystsBuy
20.00 €Target 43.67 €(+32%)52.00 €
Income statement
Net income−167.8 M€0.0% margin
Valuation
PER (forward)-14.2x
P/Book7.2x
Beta0.25
Balance sheet & cash
Market cap2.63 Bn€
Total debt4.0 M€
Free Cash Flow−144.1 M€
Debt / Equity1%
Profitability & ownership
ROE-38.1%
ROA-25.6%
% insiders0.5%
% institutions113.6%
Last declaration on 21 June 2022
Declarations0 total
No declarations found
0 of 0 declarations
About Edgewise Therapeutics, Inc.
Recent highlights include Edgewise’s early-May 2026 first-quarter financial update and clinical progress report in muscular dystrophy and cardiovascular programs. The company also outlined 2026 corporate priorities and announced participation in a RBC Capital Markets healthcare conference in May 2026. In the context of SEC Form 4 insider filings, investors should interpret insider transactions carefully, as they often reflect equity compensation or prearranged 10b5-1 plans rather than a standalone fundamental signal. Overall, Edgewise remains a specialty biotech name with meaningful scientific optionality, but also a high-risk profile typical of clinical-stage companies.
